- /
- Supported exchanges
- / SA
- / B1SX34.SA
Boston Scientific Corporation (B1SX34 SA) stock market data APIs
Boston Scientific Corporation Financial Data Overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Boston Scientific Corporation data using free add-ons & libraries
Get Boston Scientific Corporation Fundamental Data
Boston Scientific Corporation Fundamental data includes:
- Net Revenue: 20 074 M
- EBITDA: 5 339 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Boston Scientific Corporation News
New
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ...
This article first appeared on GuruFocus. Revenue: $3.3 million for Q4 2025, up 16% from $2.8 million in Q4 2024. Gross Margin: Adjusted gross margin of 66.8% for Q4 2025, up from 56.5% in Q4 2024. N...
1 Profitable Stock to Research Further and 2 Facing Challenges
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. A busi...
Boston Scientific Recall And Lawsuits Test Earnings Power And Capital Plans
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Boston Scientific (NYSE:BSX) is facing multiple new securities class action lawsuits tied t...
Is Boston Scientific (BSX) Balancing Buybacks and Litigation or Masking Deeper Electrophysiology Risks?
In late February 2026, Boston Scientific entered into a new US$3.00 billion revolving credit agreement maturing in 2031, while its board expanded the company’s share repurchase authorization to US$...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.